Report Categories
View AllRecent Articles
View All
QRVO Qorvo posts 151 percent Q1 2026 EPS beat but shares dip 076 percent in todays trading
Adobe Inc ADBE PostSession Outperformance PreEarnings Valuation and Fundamental Outlook
How Caseys CASY differentiation drives financial results Q1 2026 Better Than Expected
What is driving movement in Blackstone BX stock Q1 2026 Earnings Fall Short
Galata LATAW Stalls at 030 Consolidation Phase 20260519
SiriusPoint SPNT Up 392 Is There More Room to Run 20260518
First FUNC Q1 2026 Earnings 102 EPS Surges Past 094 Estimates
Meta Layoffs Begin This Week 8000 Job Cuts Signal AIDriven Restructuring
Stellantis and JLR Explore Joint Development for US Market Amid Tariff Pressures
POET POET Gains 673 Support Holds at 1325 20260520
Midcap and Smallcap Stocks Surge Up to 112 YTD in 2026 Analysts Weigh Sustainability
Athene ATHS Stock Consolidating at 2507 Next Move Ahead 20260520
Accenture Invests in AI Security Startup XBOW to Bolster Cyber Defense Capabilities
US Retail Sales Surpass Estimates as Consumer Demand Remains Robust
OpenAIs Potential RecordBreaking IPO Plans Draw Market Attention
Senco Gold Q4 Profit Surges 151 on Record Retail Sales and Soaring Gold Prices
Nvidias Dividend Soars 2400 as Q1 Revenue Hits 816B But Focus Remains on Growth
Bloom Energy Surges 12 on 26 Billion AI Infrastructure Partnership with Nebius
APPS Q1 2026 Earnings Strong EPS Beat Drives Positive Stock Reaction
Summit Hotel Properties Inc INN Q1 2026 Earnings Narrower Loss Beats Estimates Amid Hotel Sector Recovery
American Shared Hospital Services AMS Q1 2026 Earnings Significant EPS Miss Amid Operational Challenges
TOMI Environmental Solutions Inc Q1 2026 Earnings NarrowerThanExpected Loss Drives Stock Gain
INVA Q1 2026 Earnings Significant EPS Miss Amid Lack of Revenue Disclosure
Cameco CCJ Slightly Lower as Price Hovers Near Midpoint of Support and Resistance
SPX Technologies SPXC Declines 171 Support and Resistance Levels in Focus
Everest Group Ltd EG Holds Steady Near 353 as Insurance Sector Shows Mixed Signals
Akebia Therapeutics AKBA Edges Higher Testing Key Resistance Near 111